<DOC>
	<DOCNO>NCT03041311</DOCNO>
	<brief_summary>This study investigate potential clinical benefit trilaciclib ( G1T28 ) preserve bone marrow immune system , enhance antitumor efficacy administer carboplatin , etoposide , atezolizumab ( E/P/A ) therapy first line treatment patient newly diagnose extensive-stage SCLC . The study randomize , double-blinded , placebo-controlled design . The study include 3 study phase : Screening Phase , Treatment Phase ( induction part + maintenance part ) , Survival Follow-up Phase . The Treatment Phase begin day first dose study treatment complete Post-Treatment Visit . Approximately , 100 patient enrol study .</brief_summary>
	<brief_title>Carboplatin , Etoposide , Atezolizumab With Without Trilaciclib ( G1T28 ) , CDK 4/6 Inhibitor , Extensive Stage Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject age â‰¥18 year Unequivocally confirm diagnosis SCLC histology cytology , preferably include presence neuroendocrine feature immunohistochemistry At least 1 target lesion measurable RECIST , Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Adequate organ function Prior chemotherapy extensivestage SCLC Prior immunotherapy include limited CD137 , antiPD1 , antiPDL1 , CTLA4 . Presence symptomatic brain metastasis require immediate treatment radiation therapy steroid . History pulmonary fibrosis , organize pneumonia pneumonitis screen chest CT Active , know , suspect autoimmune disease require systemic treatment past 2 year Uncontrolled ischemic heart disease uncontrolled symptomatic congestive heart failure Known history stroke cerebrovascular accident within 6 month prior enrollment Other uncontrolled serious chronic disease condition investigator 's opinion could affect compliance followup protocol Concurrent radiotherapy site radiotherapy within 2 week prior enrollment Receipt investigational medication within 4 week prior enrollment Administration attenuate vaccine within 4 week enrollment Systemic treatment corticosteriods immunosuppressive medication within 14 day study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>CDK 4/6 Inhibitor</keyword>
	<keyword>Immune Checkpoint Inhibitor</keyword>
</DOC>